Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Eris Lifesciences Limited

Capitalization 187B 2.03B 1.76B 1.59B 1.52B 2.76B 2.86B 18.93B 7.52B 89.46B 7.61B 7.45B 323B P/E ratio 2026 *
37.6x
P/E ratio 2027 * 27.2x
Enterprise value 207B 2.24B 1.95B 1.76B 1.68B 3.06B 3.16B 20.95B 8.32B 99.01B 8.42B 8.24B 357B EV / Sales 2026 *
6.48x
EV / Sales 2027 * 5.34x
Free-Float
27.81%
Yield 2026 *
0.38%
Yield 2027 * 0.57%
1 day+0.17%
1 week-0.48%
Current month-0.49%
1 month-8.00%
3 months-15.03%
6 months-20.46%
Current year-10.23%
1 week 1,300.6
Extreme 1300.6
1,369.2
1 month 1,300.6
Extreme 1300.6
1,511
Current year 1,300.6
Extreme 1300.6
1,563
1 year 1,097.2
Extreme 1097.2
1,910
3 years 551.3
Extreme 551.3
1,910
5 years 551.3
Extreme 551.3
1,910
10 years 321
Extreme 321
1,910
Manager TitleAgeSince
Chief Executive Officer 52 26/01/2007
Director of Finance/CFO 46 27/09/2016
Chief Tech/Sci/R&D Officer - 30/04/2010
Director TitleAgeSince
Chairman 52 26/01/2007
Director/Board Member 54 26/01/2007
Director/Board Member 46 29/04/2018
Change 5d. change 1-year change 3-years change Capi.($)
+0.17%-0.48%+6.59%+121.01% 2.03B
-2.26%-2.62%+18.59%+210.22% 893B
-0.39%-1.33%+45.93%+59.65% 586B
-1.01%-4.58%+5.52%+50.54% 403B
-0.62%-11.32%+7.32%+20.69% 338B
-0.83%-4.80%+25.12%+34.27% 301B
-0.33%-5.36%+26.27%+61.94% 297B
-0.26%-3.63%+22.36%+7.63% 287B
-2.61%-3.03%+15.33%+61.40% 204B
-0.54%-2.03%+26.90%+82.65% 181B
Average -0.67%-2.79%+19.99%+71.00% 349.12B
Weighted average by Cap. -0.90%-2.60%+22.34%+88.41%

Financials

2026 *2027 *
Net sales 32B 347M 301M 272M 260M 472M 489M 3.24B 1.28B 15.29B 1.3B 1.27B 55.19B 37.29B 404M 350M 317M 302M 550M 569M 3.77B 1.5B 17.82B 1.52B 1.48B 64.31B
Net income 4.83B 52.35M 45.41M 41.06M 39.21M 71.31M 73.81M 489M 194M 2.31B 196M 192M 8.34B 6.85B 74.15M 64.32M 58.16M 55.53M 101M 105M 692M 275M 3.27B 278M 272M 11.81B
Net Debt 19.99B 217M 188M 170M 162M 295M 305M 2.02B 803M 9.55B 812M 795M 34.48B 11.86B 128M 111M 101M 96.17M 175M 181M 1.2B 476M 5.67B 482M 472M 20.45B
Logo Eris Lifesciences Limited
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD) and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Employees
3,354
Date Price Change Volume
12/03/26 1,351.60 +0.17% 40,764
11/03/26 1,349.30 -0.13% 35,750
10/03/26 1,351.10 +1.71% 100,690
09/03/26 1,328.40 -2.37% 47,652
06/03/26 1,360.70 -0.69% 19,895
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1,351.60INR
Average target price
1,743.60INR
Spread / Average Target
+29.00%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW